You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石药(01093.HK)抗肿瘤药获注册批件曝光後 股价逆市续涨逾6%
阿思达克 06-26 15:00
抗肿瘤药获注册批件的石药集团(01093.HK)连升第三天,今天股价逆大市高见15.14元,创逾三个月高,现造15.08元,逆涨6.2%,为最好蓝筹,成交5,431万股,已接近假前全日成交量,涉资8.07亿元。石药日前公布,附属欧意药业开发的抗肿瘤药「注射用硼替佐米(3.5mg)Z」已获国家药监管颁发药品注册批件,为国内该品种首个视同通过质量和疗效一致性评价仿制药。

港股假後复市追跌放假期间欧美及区内跌幅,报24,576,续吐205点或0.8%,但成交额仅754亿元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account